Allianz Asset Management GmbH Decreases Stock Position in United Therapeutics Corporation $UTHR

Allianz Asset Management GmbH lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 29.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 45,072 shares of the biotechnology company’s stock after selling 19,018 shares during the period. Allianz Asset Management GmbH’s holdings in United Therapeutics were worth $18,895,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. AQR Capital Management LLC raised its position in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Invesco Ltd. raised its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. Assetmark Inc. raised its holdings in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after buying an additional 197,384 shares during the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics during the second quarter worth $136,453,000. Finally, Amundi grew its holdings in shares of United Therapeutics by 3.6% during the second quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock valued at $107,113,000 after buying an additional 12,633 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have sold 542,214 shares of company stock valued at $260,031,533. Insiders own 10.30% of the company’s stock.

United Therapeutics Trading Up 1.3%

Shares of UTHR stock opened at $485.36 on Friday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The stock has a 50 day moving average of $486.75 and a 200 day moving average of $426.57. The stock has a market cap of $20.90 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.55 and a beta of 0.85.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.